193 related articles for article (PubMed ID: 28224698)
1. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.
Vanhove T; Bouwsma H; Hilbrands L; Swen JJ; Spriet I; Annaert P; Vanaudenaerde B; Verleden G; Vos R; Kuypers DRJ
Am J Transplant; 2017 Sep; 17(9):2372-2380. PubMed ID: 28224698
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Suetsugu K; Mori Y; Yamamoto N; Shigematsu T; Miyamoto T; Egashira N; Akashi K; Masuda S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096684
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
[TBL] [Abstract][Full Text] [Related]
4. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
[TBL] [Abstract][Full Text] [Related]
7. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
8. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
[TBL] [Abstract][Full Text] [Related]
10. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
[TBL] [Abstract][Full Text] [Related]
11. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.
Calabrese DR; Florez R; Dewey K; Hui C; Torgerson D; Chong T; Faust H; Rajalingam R; Hays SR; Golden JA; Kukreja J; Singer JP; Greenland JR
Clin Transplant; 2018 Aug; 32(8):e13332. PubMed ID: 29920787
[TBL] [Abstract][Full Text] [Related]
12. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
[TBL] [Abstract][Full Text] [Related]
13. A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen.
Woillard JB; Gatault P; Picard N; Arnion H; Anglicheau D; Marquet P
Am J Transplant; 2018 Dec; 18(12):2905-2913. PubMed ID: 29689130
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
16. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
17. Influence of
Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
Pharmacogenet Genomics; 2008 Oct; 18(10):861-8. PubMed ID: 18704002
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients.
Kuypers DR; de Loor H; Naesens M; Coopmans T; de Jonge H
Pharmacogenet Genomics; 2014 Dec; 24(12):597-606. PubMed ID: 25322286
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
Vanhove T; Hasan M; Annaert P; Oswald S; Kuypers DRJ
Br J Clin Pharmacol; 2017 Nov; 83(11):2406-2415. PubMed ID: 28603840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
